By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – As Illumina shareholders prepare for a vote that could determine the future of Roche's hostile bid for the San Diego company, an investment analyst today said that Roche is unlikely to make any headway in getting a deal done and only has a couple of other options.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.